Anagrelide

Breastfeeding
  • TRADE NAMES: Agrylin (Shire); Xagrid (Shire)
  • INDICATIONS: Essential thrombocytopenia; to reduce elevated platelet count and the risk of thrombosis
  • CLASS: Phospholipase A2 inhibitor
  • HALF-LIFE: 1.3 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Aminophylline, Aspirin, Cilostazol, Enoximone, Fluvoxamine, Fondaparinux, Inamrinone, Milrinone, Olprinone, Sucralfate

PREGNANCY CATEGORY: C

Contraindicated in patients with severe hepatic impairment.

Our database has 42 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OTIC.
RESPIRATORY.
OTHER.


Page last updated 08/02/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top